Surgical Science Sweden AB
STO:SUS
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
113.7
193.3
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one SUS stock under the Base Case scenario is 181.68 SEK. Compared to the current market price of 126.6 SEK, Surgical Science Sweden AB is Undervalued by 30%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Surgical Science Sweden AB
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for SUS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Surgical Science Sweden AB
Balance Sheet Decomposition
Surgical Science Sweden AB
Current Assets | 1.1B |
Cash & Short-Term Investments | 667.1m |
Receivables | 126.3m |
Other Current Assets | 270m |
Non-Current Assets | 3.9B |
Long-Term Investments | 5m |
PP&E | 75.4m |
Intangibles | 3.8B |
Other Non-Current Assets | 15.6m |
Current Liabilities | 256.3m |
Other Current Liabilities | 256.3m |
Non-Current Liabilities | 113.4m |
Other Non-Current Liabilities | 113.4m |
Earnings Waterfall
Surgical Science Sweden AB
Revenue
|
838.2m
SEK
|
Cost of Revenue
|
-264m
SEK
|
Gross Profit
|
574.3m
SEK
|
Operating Expenses
|
-426.5m
SEK
|
Operating Income
|
147.8m
SEK
|
Other Expenses
|
50m
SEK
|
Net Income
|
197.7m
SEK
|
Free Cash Flow Analysis
Surgical Science Sweden AB
SEK | |
Free Cash Flow | SEK |
Surgical Science, while navigating the aftermath of an October 7 tragedy in Tel Aviv, reported minimal impact on business, with strong team cohesion and continued operations. Q3 brought a modest 3% year-over-year growth to SEK 210 million in net sales, or 1% when excluding foreign exchange effects. The highlight was in license revenues, which leapt by 38%, markedly outpacing the market's installed base and procedural growth, which registered at 13% and 19% respectively. Educational Products sales fell 9%, but adjusting for an exceptional prior U.S. order and a sluggish China market, the segment grew robustly elsewhere. Profit margins significantly improved, with profit per share skyrocketing by 65%. Despite uncertain macroeconomics, the company remains positive, observing signs of recovery in China and staying on course for their 2026 goals.
What is Earnings Call?
SUS Profitability Score
Profitability Due Diligence
Surgical Science Sweden AB's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
Score
Surgical Science Sweden AB's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
SUS Solvency Score
Solvency Due Diligence
Surgical Science Sweden AB's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Surgical Science Sweden AB's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SUS Price Targets Summary
Surgical Science Sweden AB
According to Wall Street analysts, the average 1-year price target for SUS is 189.52 SEK with a low forecast of 136.35 SEK and a high forecast of 236.25 SEK.
Dividends
Current shareholder yield for SUS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
SUS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Surgical Science Sweden AB engages in the development of simulators for laparoscopic medical training. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2017-06-19. The systems comprise LapSim, EndoSim and TeamSim trainings. Each training combine graphics and cognitive instruction, imply navigation on touch screens and feature tactile feedback technology. The LapSim trainings consist of laparoscopic exercises that range from basic navigation to advanced suturing, the EndoSim endoscopic exercises range from functions of the scope handle and tube, to loop reduction. The TeamSim comprises procedure modules to train in a real world operation room environment and helps to build team communication skills in crisis and routine situations. The training systems are used by medical training centers and institutes worldwide for practice, validation and certification of students, surgeons, and medical doctors.
Contact
IPO
Employees
Officers
The intrinsic value of one SUS stock under the Base Case scenario is 181.68 SEK.
Compared to the current market price of 126.6 SEK, Surgical Science Sweden AB is Undervalued by 30%.